Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity

  title={Tissue selectivity and potential clinical applications of trenbolone (17$\beta$-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity},
  author={Joshua F. Yarrow and Sean C. McCoy and Stephen E. Borst},

Figures from this paper

17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.

Low-dose administration of the non-5α-reducible androgen TREN maintains prostate mass and hemoglobin concentrations near the level of shams while producing potent myotrophic actions in skeletal muscle and partial protection against orchiectomy-induced bone loss and visceral fat accumulation.

Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health

A brief review of the history of AAS is provided and clinical applications of two of the more well-known AAS: n androlone and oxandrolone are discussed, which exhibit favorable myotrophic/androgenic ratios and have been investigated for effectiveness in numerous disease states.


The results indicated that 17a-19-nortestosterone selectively disturbs the viability of HeLa cells without greatly affecting other cancer cell types and intact fibroblasts.

Cardiovascular Health, Testosterone, and Oxandrolone: Leveraging the Myotrophic-Androgenic Ratio in Males with a Sarcopenic Obese Phenotype

Overall, oxandrolone shows promise related to its pharmacology in patients with low muscle tone and significant adiposity, namely cardiometabolic profiles if administered with clinical prudence due to its novel structure, metabolism, and effects.

Beck: Aromatase and Testosterone Administration

In conclusion, androgens are able to induce direct effects on musculoskeletal and adipose tissue, independent of aromatase activity, as well as producing potent myotrophic effects in the LABC muscle and maintained fat-mass at the level of Shams.



Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.

Comparisons and in vitro studies reveal novel differences in the molecular mechanisms by which S-22, a nonsteroidal SARM, and DHT mediate their pharmacological effects.

Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis.

Collectively, this novel compound served as a prototype for SARMs, which had unique tissue selectivity with high potency for bone formation and lower impact upon sex accessory tissues.

Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.

Although S-1 and finasteride showed very similar suppressive effects in the prostate of intact male rats, they decreased prostate size via different mechanisms of action, indicating that SARMs may demonstrate clinical utility as single agent or combination therapy for BPH.

Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor

It is concluded that MGA and TBA metabolites may be hor‐monally active substances, which will be present in edible tissues and in manure, and detailed investigations on biodegradation, distribution and bio‐efficacy of these substances are necessary.

Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens

Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.

The potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window.

Selective non-steroidal inhibitors of 5α-reductase type 1

Selective non-steroidal inhibitors of 5 alpha-reductase type 1.

This paper will review the major classes of 5 alpha R inhibitors focusing in particular on non-steroidal inhibitors and on structural features that enhance the selectivity versus the type 1 isozyme.

Evaluation of the model anti-androgen flutamide for assessing the mechanistic basis of responses to an androgen in the fathead minnow (Pimephales promelas).

The results of these studies provide data demonstrating the validity of using the fathead minnow as a model species for detecting EDCs that exert toxicity through interactions with the AR, and antagonism of an AR receptor-mediated response in vivo.